Funding for this research was provided by:
Text and Data Mining valid from 2018-10-22
Received: 22 January 2018
Accepted: 16 October 2018
First Online: 22 October 2018
Ethics approval and consent to participate
: The study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements. Since this was a retrospective study of an anonymised database and had no influence on patient care, ethics committee approval was not required. Approval was obtained from the <i>Commission Nationale de l’Informatique et des Libertés</i> (CNIL) with respect to respecting the confidentiality of individual patient data.
: Not Applicable.
: AS reports receiving honoraria for participation in advisory boards, lecturing or consulting from Boehringer-Ingelheim, BMS, MSD, and Roche. IDZ reports personal fees from BMS related to the conduct of the study and personal fees from BMS unrelated to this study. PC reports personal fees from BMS related to the conduct of the study. VW reports receiving honoraria from Astra-Zeneca, Boehringer-Ingelheim, MSD, Pierre-Fabre Oncology, Lilly, Roche, Bristol Myers Squibb, and Novartis, and compensation for meeting expenses from Lilly, Merck Serono, Novartis, Pierre-Fabre Oncology and Boehringer Ingelheim. CC reports receiving honoraria for attending scientific meetings, lecturing, organising research or consulting from AstraZeneca, Boehringer Ingelheim, GSK, Roche, Sanofi Aventis, Lilly, Novartis, MSD, BMS and Amgen. JF, DD, PC and PJS declare that they have no relevant conflicts of interest. AFG and FEC are salaried employees of BMS, the funders of the study. CB, CT and AV are employees or shareholders of HEVA, who were contracted by the funder for operational management of the study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.